Monocyte or white blood cell counts and β(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide

BACKGROUND: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. OBJECTIVES: We hypothesized that a durable response to daratumumab could be predicted by the ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751172/
https://www.ncbi.nlm.nih.gov/pubmed/36530751
http://dx.doi.org/10.1177/20406207221142487

Ejemplares similares

Ejemplares similares